REGEN BIOPHARMA, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $236.6K | $236.6K | $126.6K | $125.5K | $61.2K | $110.0K | $110.0K | $100.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $11.7K | $153.7K | $212.3K | $158.1K | $36.7K | $13.3K | $45.6K | $374.4K |
| SG&A Expense | $75.1K | $58.9K | $45.0K | $28.1K | $119.5K | $249.7K | $500.6K | $743.8K |
| Operating Income | $-338.5K | $-417.2K | $-687.0K | $-339.6K | $-200.8K | $-209.3K | $-756.8K | $-1.4M |
| Operating Margin | -143.1% | -176.4% | -542.8% | -270.6% | -328.1% | -190.3% | -688.0% | -1,425.8% |
| Interest Expense | — | — | $58.6K | $138.7K | $316.0K | $333.4K | $295.2K | $259.1K |
| Pretax Income | $-1.3M | $-668.3K | $1.2M | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | — | — | — | — | — | — |
| Net Income | $-1.3M | $-668.3K | $1.2M | $2.4M | $-6.8M | $3.4M | $-2.6M | $-4.7M |
| Net Margin | -538.8% | -282.5% | 913.8% | 1,946.8% | -11,055.4% | 3,104.0% | -2,384.7% | -4,715.2% |
| EPS (Basic) | $-0.05 | $-0.03 | $0.05 | $0.12 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | $-0.05 | $-0.03 | $0.05 | $0.12 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 23.5M | 24.7M | 21.2M | 28.22B | 18.07B | 16.92B | 24.85B | 25.55B |
| Shares Outstanding (Diluted) | 23.5M | 24.7M | 21.2M | 18.8M | 18.07B | 16.92B | 24.85B | 25.55B |
| Dividends Per Share | — | — | — | — | — | — | — | — |